Pontin is a critical regulator for AML1-ETO-induced leukemia

Leukemia

Volumn 28, Issue 6, 2014, Pages 1271-1279

  Breig, O ^a   Bras, S ^a   Martinez Soria, N ^b   Osman, D ^a   Heidenreich, O ^b   Haenlin, M ^a   Waltzer, L ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

acute myeloid leukemia; AML1 ETO; Drosophila; genetic screen; PONTIN RUVBL1

Indexed keywords

TRANSCRIPTION FACTOR RUNX1;

ANIMAL CELL; ARTICLE; BLOOD CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL RENEWAL; DOWN REGULATION; DROSOPHILA MELANOGASTER; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; NONHUMAN; PHENOTYPE; PONTIN GENE; PRIORITY JOURNAL; REGULATOR GENE; RNA INTERFERENCE; SUPPRESSOR GENE; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL CYCLE; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA HELICASES; DROSOPHILA MELANOGASTER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84902120268     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.376     Document Type: Article

References (55)

1. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80: 1825-1831.
2. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993; 12: 2715-2721. (Pubitemid 23218321)
3. Lam K, Zhang DE. RUNX1 and RUNX1-ETO: Roles in hematopoiesis and leukemogenesis. Front Biosci 2012; 17: 1120-1139.
4. Wichmann C, Becker Y, Chen-Wichmann L, Vogel V, Vojtkova A, Herglotz J et al. Dimer-Tetramer transition controls RUNX1/ETO leukemogenic activity. Blood 2010; 116: 603-613.
5. Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 2012; 26: 1829-1841.
6. Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA et al. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 2012; 120: 4038-4048.
7. Saeed S, Logie C, Francoijs KJ, Frige G, Romanenghi M, Nielsen FG et al. Chromatin accessibility, p300, and histone acetylation define PML-RARalpha and AML1-ETO binding sites in acute myeloid leukemia. Blood 2012; 120: 3058-3068.
8. Hatlen MA, Wang L, Nimer SD. AML1-ETO driven acute leukemia: Insights into pathogenesis and potential therapeutic approaches. Front Med 2011; 6: 248-262.
9. Schwieger M, Lohler J, Friel J, Scheller M, Horak I, Stocking C. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 2002; 196: 1227-1240. (Pubitemid 35304188)
10. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115: 2159-2168. (Pubitemid 41134157)
11. Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011; 108: 2450-2455.
12. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2012; 333: 765-769.
13. Lo MC, Peterson LF, Yan M, Cong X, Jin F, Shia WJ et al. Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML. Blood 2012; 120: 1473-1484.
14. Zhang Y, Wang J, Wheat J, Chen X, Jin S, Sadrzadeh H et al. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/beta-catenin signaling pathway. Blood 2013; 121: 4906-4916.
15. Li Y, Gao L, Luo X, Wang L, Gao X, Wang W et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 2013; 121: 499-509.
16. Polesello C, Roch F, Gobert V, Haenlin M, Waltzer L. Modeling cancers in Drosophila. Prog Mol Biol Transl Sci 2011; 100: 51-82.
17. Crozatier M, Vincent A. Drosophila: A model for studying genetic and molecular aspects of haematopoiesis and associated leukaemias. Dis Model Mech 2011; 4: 439-445.
18. Osman D, Gobert V, Ponthan F, Heidenreich O, Haenlin M, Waltzer L. A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO. Proc Natl Acad Sci USA 2009; 106: 12043-12048.
19. Bras S, Martin-Lanneree S, Gobert V, Auge B, Breig O, Sanial M et al. Myeloid leukemia factor is a conserved regulator of RUNX transcription factor activity involved in hematopoiesis. Proc Natl Acad Sci USA 2012; 109: 4986-4991.
20. Grigoletto A, Lestienne P, Rosenbaum J. The multifaceted proteins Reptin and Pontin as major players in cancer. Biochim Biophys Acta 2011; 1815: 147-157.
21. Haurie V, Menard L, Nicou A, Touriol C, Metzler P, Fernandez J et al. Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. Hepatology 2009; 50: 1871-1883.
22. Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 2003; 101: 3157-3163. (Pubitemid 36858010)
23. Martinez N, Drescher B, Riehle H, Cullmann C, Vornlocher HP, Ganser A et al. The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer 2004; 4: 44.
24. Gobert V, Osman D, Bras S, Auge B, Boube M, Bourbon HM et al. A genome-wide RNA interference screen identifies a differential role of the mediator CDK8 module subunits for GATA/ RUNX-Activated transcription in Drosophila. Mol Cell Biol 2010; 30: 2837-2848.
25. Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H et al. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia 2013; 27: 718-721.
26. Breig O, Theoleyre O, Douablin A, Baklouti F. Subtle distinct regulations of late erythroid molecular events by PI3K/AKT-mediated activation of Spi-1/PU.1 oncogene autoregulation loop. Oncogene 2010; 29: 2807-2816.
27. Schmid R, Baum P, Ittrich C, Fundel-Clemens K, Huber W, Brors B et al. Comparison of normalization methods for Illumina BeadChip HumanHT-12 v3. BMC Genomics 2010; 11: 349.
28. Bauer A, Chauvet S, Huber O, Usseglio F, Rothbacher U, Aragnol D et al. Pontin52 and reptin52 function as antagonistic regulators of beta-catenin signalling activity. EMBO J 2000; 19: 6121-6130.
29. Zuberi K, Franz M, Rodriguez H, Montojo J, Lopes CT, Bader GD et al. GeneMANIA prediction server 2013 update. Nucleic Acids Res 2013; 41: W115-W122.
30. Wildonger J, Mann RS. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. Development 2005; 132: 2263-2272. (Pubitemid 40872797)
31. Sinenko SA, Hung T, Moroz T, Tran QM, Sidhu S, Cheney MD et al. Genetic manipulation of AML1-ETO-induced expansion of hematopoietic precursors in a Drosophila model. Blood 2010; 116: 4612-4620.
32. Bereshchenko O, Mancini E, Luciani L, Gambardella A, Riccardi C, Nerlov C. Pontin is essential for murine hematopoietic stem cell survival. Haematologica 2012; 97: 1291-1294.
33. Feng Y, Lee N, Fearon ER. TIP49 regulates beta-catenin-mediated neoplastic transformation and T-cell factor target gene induction via effects on chromatin remodeling. Cancer Res 2003; 63: 8726-8734. (Pubitemid 38064050)
34. Dugan KA, Wood MA, Cole MD. TIP49, but not TRRAP, modulates c-Myc and E2F1 dependent apoptosis. Oncogene 2002; 21: 5835-5843. (Pubitemid 35007233)
35. Ducat D, Kawaguchi S, Liu H, Yates 3rd JR, Zheng Y. Regulation of microtubule assembly and organization in mitosis by the AAA+ ATPase Pontin. Mol Biol Cell 2008; 19: 3097-3110.
36. Watkins NJ, Lemm I, Ingelfinger D, Schneider C, Hossbach M, Urlaub H et al. Assembly and maturation of the U3 snoRNP in the nucleoplasm in a large dynamic multiprotein complex. Mol Cell 2004; 16: 789-798. (Pubitemid 39586536)
37. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med 2012; 18: 1118-1122.
38. Bellosta P, Hulf T, Balla Diop S, Usseglio F, Pradel J, Aragnol D et al. Myc interacts genetically with Tip48/Reptin and Tip49/Pontin to control growth and proliferation during Drosophila development. Proc Natl Acad Sci USA 2005; 102: 11799-11804. (Pubitemid 41170805)
39. Wood MA, McMahon SB, Cole MD. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol Cell 2000; 5: 321-330. (Pubitemid 30628090)
40. Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer 2010; 1: 605-616.
41. Fujiwara K, Yuwanita I, Hollern DP, Andrechek ER. Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors. Cancer Res 2011; 71: 1924-1932.
42. Li FX, Zhu JW, TessemJS, Beilke J, Varella-Garcia M, Jensen J et al. The development of diabetes in E2f1/E2f2 mutant mice reveals important roles for bone marrow-derived cells in preventing islet cell loss. Proc Natl Acad Sci USA 2003; 100: 12935-12940. (Pubitemid 37340003)
43. Di Stefano L, Jensen MR, Helin K. E2F7 a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. EMBO J 2003; 22: 6289-6298. (Pubitemid 37522586)
44. Salvatori B, Iosue I, Mangiavacchi A, Loddo G, Padula F, Chiaretti S et al. The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. Cell Death Dis 2012; 3: E413.
45. Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 2008; 132: 945-957. (Pubitemid 351381739)
46. Gessner A, Thomas M, Castro PG, Buchler L, Scholz A, Brummendorf TH et al. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia 2010; 24: 1751-1759.
47. Osaki H, Walf-Vorderwulbecke V, Mangolini M, Zhao L, Horton SJ, Morrone G et al. The AAA(+) ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis. Leukemia 2013; 27: 1461-1468.
48. Huang X, Spencer GJ, Lynch JT, Ciceri F, Somerville TDD, Somervaille TCP. Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells. Leukemia 2013; e-pub ahead of print 12 November 2013; doi:10.1038/leu.2013.316.
49. Menard L, Taras D, Grigoletto A, Haurie V, Nicou A, Dugot-Senant N et al. In vivo silencing of Reptin blocks the progression of human hepatocellular carcinoma in xenografts and is associated with replicative senescence. J Hepatol 2010; 52: 681-689.
50. Elkaim J, Castroviejo M, Bennani D, Taouji S, Allain N, Laguerre M et al. First identification of small-molecule inhibitors of Pontin by combining virtual screening and enzymatic assay. Biochem J 2012; 443: 549-559.
51. Rottbauer W, Saurin AJ, Lickert H, Shen X, Burns CG, Wo ZG et al. Reptin and pontin antagonistically regulate heart growth in zebrafish embryos. Cell 2002; 111: 661-672. (Pubitemid 35441248)
52. Li W, Zeng J, Li Q, Zhao L, Liu T, Bjorkholm M et al. Reptin is required for the transcription of telomerase reverse transcriptase and over-expressed in gastric cancer. Mol Cancer 2010; 9: 132.
53. Gonzalez C. Drosophila melanogaster: A model and a tool to investigate malignancy and identify new therapeutics. Nat Rev Cancer 2013; 13: 172-183.
54. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
55. Bergerson RJ, Collier LS, Sarver AL, Been RA, Lugthart S, Diers MD et al. An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model. Blood 2012; 119: 4512-4523.